Please assess the completion status of the following clinical trial:

Trial Title: Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 65 years of age or older~* must anticipate taking warfarin for at least 4 weeks for VTE prophylaxis after hip or knee arthroplasty~* must be able to give written, informed consent~* must have venous access~* must not be institutionalized, incarcerated at the time of enrollment (nursing home okay)~* must have life expectancy \> 6 months~* must have plans to have regular INR monitoring~* willing/able to follow-up in 3-7 weeks with a Doppler Ultrasound~Exclusion Criteria:~* Baseline INR \> 1.35~* knowledge of CYP2C9, VKORC1, or CYP4F2 genotype~* knowledge of warfarin dose requirements from prior warfarin therapy~* absolute contraindication or allergy to warfarin therapy (e.g. pregnancy)~* receiving or planning to receive any anticoagulant besides warfarin (if low molecular weight heparin (LMWH) or subcutaneous heparin is deemed necessary by the clinician after enrollment, such patients will be allowed to remain in the study)~* unlikely to be compliant (e.g. due to history of non-compliance, or alcoholism)~* known thrombophilia, bleeding disorder, or history of serious bleed in the past 2 years (unless caused by trauma)~* personal history of venous thromboembolism

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Target INR 1.8 and Pharmacogenetic (Type: EXPERIMENTAL): The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
- Target INR 2.5 and Pharmacogenetic (Type: EXPERIMENTAL): The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
- Target INR 1.8 and Clinical (Type: EXPERIMENTAL): The target INR is 1.8. Warfarin initiation is via clinical dosing.
- Target INR 2.5 and Clinical (Type: NO_INTERVENTION): The target INR is 2.5. Warfarin initiation is via clinical dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).